title: Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial.
abstract: BACKGROUND
  Antimuscarinic agents are currently the predominant treatment option for the clinical management of the symptoms of overactive bladder (OAB). However, low rates of persistence with these agents highlight the need for novel, effective and better-tolerated oral pharmacological agents. Mirabegron is a β3-adrenoceptor agonist developed for the treatment of OAB, with a mechanism of action distinct from that of antimuscarinics. In a randomized, double-blind, placebo- and active-controlled Phase 3 trial conducted in Europe and Australia (NCT00689104), mirabegron 50 mg and 100 mg resulted in statistically significant reductions from baseline to final visit, compared with placebo, in the co-primary end points - mean number of incontinence episodes/24 h and mean number of micturitions/24 h. We conducted a post hoc, subgroup analysis of this study in order to evaluate the efficacy of mirabegron in treatment-naïve patients and patients who had discontinued prior antimuscarinic therapy because of insufficient efficacy or poor tolerability.
  
  
  METHODS
  Patients were randomized to placebo, mirabegron 50 or 100 mg, or tolterodine extended release (ER) 4 mg orally, once-daily, for 12 weeks. For the post hoc analysis, the primary patient population was divided into the following subgroups: (1) patients who had not received any prior antimuscarinic OAB medication (treatment-naïve) and (2) patients who had received prior antimuscarinic OAB medication. The latter subgroup was further subdivided into patients who discontinued due to: (3) insufficient efficacy or (4) poor tolerability. Analysis of the co-primary efficacy endpoints by subgroup was performed using analysis of covariance with treatment group, subgroup, sex, geographical region, and subgroup-by-treatment interaction as fixed factors; and baseline value as a covariate.
  
  
  RESULTS
  Mirabegron, 50 mg and 100 mg once-daily, demonstrated similar improvements in the frequency of incontinence episodes and micturitions in OAB patients who were antimuscarinic-naïve and who had discontinued prior antimuscarinic therapy. While mirabegron demonstrated improvements in incontinence and micturition frequency in patients who had discontinued prior antimuscarinic therapy due to insufficient efficacy, the response to tolterodine was similar to that of placebo.
  
  
  CONCLUSIONS
  In this post hoc subgroup analysis, mirabegron provided treatment benefits in OAB patients who were antimuscarinic treatment-naïve and in patients who had received prior antimuscarinic treatment.
authors.affiliation: Urogynaecology Department, St Mary's Hospital, Imperial College, London, UK. vik.khullar@imperial.ac.uk.
authors.forename: Vik
authors.initials: V
authors.lastname: Khullar
authors.forename: Javier
authors.initials: J
authors.lastname: Cambronero
authors.forename: Javier C
authors.initials: JC
authors.lastname: Angulo
authors.forename: Marianne
authors.initials: M
authors.lastname: Wooning
authors.forename: Mary Beth
authors.initials: MB
authors.lastname: Blauwet
authors.forename: Caroline
authors.initials: C
authors.lastname: Dorrepaal
authors.forename: Nancy E
authors.initials: NE
authors.lastname: Martin
mesh_terms: D000083:Acetanilides / Q000008:administration & dosage*; D000368:Aged; D000369:Aged, 80 and over; D001315:Australia; D004305:Dose-Response Relationship, Drug; D005060:Europe; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage*; D015995:Prevalence; D012189:Retrospective Studies; D013844:Thiazoles / Q000008:administration & dosage*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D064804:Urological Agents / Q000008:administration & dosage
chemical_list: D000083:Acetanilides; D018727:Muscarinic Antagonists; D013844:Thiazoles; D064804:Urological Agents; C520025:mirabegron
references.citation: Eur Urol. 2008 Sep;54(3):543-62
references.pmid: 18599186
references.citation: Int J Urol. 2009 Feb;16(2):126-42
references.pmid: 19228224
references.citation: BJU Int. 2007 Nov;100(5):987-1006
references.pmid: 17922784
references.citation: Urology. 2002 May;59(5 Suppl 1):25-9
references.pmid: 12007519
references.citation: Int J Clin Pract. 2011 May;65(5):567-85
references.pmid: 21489081
references.citation: Eur Urol. 2006 Sep;50(3):440-52; discussion 453
references.pmid: 16753253
references.citation: JAMA. 2011 Dec 21;306(23):2612-3
references.pmid: 22187283
references.citation: Int J Clin Pract. 2009 Apr;63(4):560-7
references.pmid: 19348029
references.citation: BJU Int. 2010 May;105(9):1276-82
references.pmid: 19912188
references.citation: BJU Int. 2011 Oct;108(7):1132-8
references.pmid: 21231991
references.citation: BJU Int. 2012 Dec;110(11):1767-74
references.pmid: 22409769
references.citation: Eur Urol. 2005 Jul;48(1):5-26
references.pmid: 15885877
references.citation: Curr Opin Urol. 2003 Jul;13(4):285-91
references.pmid: 12811292
references.citation: J Urol. 2013 Apr;189(4):1388-95
references.pmid: 23079373
references.citation: Clin Ther. 2008 Oct;30(10):1766-81
references.pmid: 19014833
references.citation: N Engl J Med. 2006 Apr 20;354(16):1667-9
references.pmid: 16625007
references.citation: J Pharmacol Exp Ther. 2007 May;321(2):642-7
references.pmid: 17293563
references.citation: Arch Intern Med. 2012 Feb 27;172(4):375; author reply 375-6
references.pmid: 22371934
references.citation: Eur Urol. 2013 Feb;63(2):283-95
references.pmid: 23182126
references.citation: Eur Urol. 2008 Jul;54(1):226-30
references.pmid: 18439750
references.citation: J Manag Care Pharm. 2008 Apr;14(3):291-301
references.pmid: 18439051
references.citation: PLoS One. 2011 Feb 23;6(2):e16718
references.pmid: 21373193
references.citation: Am J Manag Care. 2005 Jul;11(4 Suppl):S121-9
references.pmid: 16161385